Adaptimmune Therapeutics plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Adaptimmune Therapeutics plc
Melanoma treatment Amtagvi is US FDA’s biologics center’s first novel approval of 2024.
Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.
Setting a strategic focus on solid cancers with its enhanced PRIME CAR-T technology, Koji Tamada, CEO of Noile-Immune, shared the Japanese bioventure's collaboration strategies and views on the next generation of cell therapies.
The German biotech presented updated data at ESMO showing strong efficacy in ovarian cancer and other solid tumors, albeit with a higher degree of adverse events, particularly cytokine release syndrome.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Adaptimmune LLC
- Adaptimmune Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.